


Please type a plus sign (+) inside this box → 

Substitute for form 1449A/B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Use as many sheets as necessary)</i>				Complete if Known	
				Application Number	10/526,697
				Filing Date	May 5, 2005
				First Named Inventor	Dudley et al.
				Group Art Unit	1644
				Examiner Name	Michail A. BELYAVSKYI
				Attorney Docket Number	233876
				Client Reference No.	E-275-2002/1-US-02
Sheet	1	of	1		

U.S. PATENT DOCUMENTS						
Examiner Initials	Doc. No.	U.S. Patent Document		Name of Patentee or Applicant	Date of Publication	Filing Date If Appropriate
		Application or Patent Number	Kind Code			

FOREIGN PATENT DOCUMENTS							
Examiner Initials	Doc. No.	Foreign Patent Document			Name of Patentee or Applicant	Date of Publication	Translation *
		Office	Application or Patent Number	Kind Code			

OTHER - NON PATENT LITERATURE DOCUMENTS			
Examiner Initials	Doc. No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number (s), publisher, city and/or country where published.	Translation *
	AW	EP Patent Application No. 03794636.5 Supplementary European Search Report dated January 24, 2011	
	AX	DUDLEY, <i>Journal of Immunotherapy</i> , 22(4), 288-298 (July 1, 1999);	
	AY	DUDLEY, <i>Science, American Association for the Advancement of Science</i> , 298(5594), 805-854 (October 25, 2002);	
	AZ	OVERWIJK et al., <i>The Cancer Journal from Scientific American (Online)</i> , 1-7 (February 2008), retrieved from the internet: URL: http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2538796/pdf/nihms65816.pdf	
	BA	ROSENBERG et al., <i>Journal of the National Cancer Institute</i> , 86(15), 1159-1166 (August 3, 1994).	

Examiner Signature	Date Considered
--------------------	-----------------

* If the reference is not in English, then at least one of the following is provided: (a) an English translation in whole or in part or (b) a concise statement of relevance in the form of, for example, an English language counterpart, an English-language abstract, or an English-language version of the search report or action by a foreign patent office in a counterpart foreign application indicating the degree of relevance found by the foreign office.